Cengiz Oner

Eskisehir Osmangazi University, Eskişehir, Eskisehir, Turkey

Are you Cengiz Oner?

Claim your profile

Publications (14)29.21 Total impact

  • Ayşe Ekim, Onur Armağan, Cengiz Oner
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy of transcutaneous electrical nerve stimulation (TENS) therapy on shoulder pain and upper extremity functions in hemiplegic patients. Total of 19 hemiplegic patients with shoulder pain were as consecutive randomly assigned into two groups. TENS was applied in group 1 (n = 10) for 20 minutes and group 2 (n = 9) received placebo stimulation. Conventional rehabilitation program were applied total 15 sessions during a period of 3 week in both groups.The visual analog scale (VAS) to evaluate shoulder pain, Barthel Index (BI) for daily-life activities (DLA) were used. The shoulder passive range of motions (PROMs) and Brunnstrom stage of motor recovery were measured. Clinical parameters were similar at baseline. In both groups, significant improvements were observed in VAS and BI (group 1: p<0.001; group 2: p<0.05). In VAS (p<0.001), and BI (p<0.05) were showed significant improvements in favor of group 1, when compared with the groups. In PROMs of abduction and external rotation of shoulder significant improvements were observed in only group 1 (p<0.001, p<0.001 respectively). There was not any significant improvement on Brunnstrom stage of motor recovery in both groups (p>0.05). In conclusion that TENS therapy together with conventional rehabilitation could be used as a good alternative therapy in patients with hemiplegic shoulder pain.
    Agri: Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology 01/2008; 20(1):41-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Turner's syndrome (TS) is a chromosomal disorder where phenotypic females have either a missing chromosome (45 X0) or a structural aberration of one of the chromosomes. It is possible for TS to accompany such autoimmune diseases as thyroid diseases, inflammatory intestinal diseases, diabetes mellitus, psoriatic arthritis and juvenile rheumatoid arthritis. Herein, we present an unusual case with Ankylosing spondylitis (AS) and autoimmune thyroiditis associated with TS. We suggest that the possibility that TS patients may also develop such other diseases as AS apart from the already known accompanying autoimmune diseases should not be ruled out when monitoring TS patients.
    Rheumatology International 11/2007; 27(12):1177-80. · 2.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: the aim of the present study was to evaluate the efficacy of low level laser therapy (LLLT) in patients with rheumatoid arthritis (RA) with carpal tunnel syndrome (CTS). a total of 19 patients with the diagnosis of CTS in 19 hands were included and randomly assigned to two treatment groups; LLLT (Group 1) (10 hands) with dosage 1.5 J/ per point and placebo laser therapy group (Group 2) (9 hands). A Galium-Aluminum-Arsenide diode laser device was used as a source of low power laser with a power output of 50 mW and wavelength of 780 nm. All treatments were applied once a day on week days for a total period of 10 days. Clinical assessments were performed at baseline, at the end of the treatment and at month 3. Tinel and Phalen signs were tested in all patients. Patients were evaluated for such clinical parameters as functional status scale (FSS), visual analogue scale (VAS), symptom severity scale (SSS) and grip-strength. However, electrophysiological examination was performed on all hands. Results were given with descriptive statistics and confidence intervals between group means at 3 months adjusted for outcome at baseline and for the difference between unadjusted group proportions. clinical and electrophysiological parameters were similar at baseline in both groups. Improvements were significantly more pronounced in the LLLT group than placebo group. A comparison between groups showed significant improvements in pain score and functional status scale score. Group mean differences at 3 months adjusted at baseline were found to be statistically significant for pain score and functional status scale score. The 95% significant confidence intervals were [-15 - (-5)] and [-5 - (-2)] respectively. There were no statistically significant differences in other clinical and electrophysiological parameters between groups at 3 months. our study results indicate that LLLT and placebo laser therapy seems to be effective for pain and hand function in CTS. We, therefore, suggest that LLLT may be used as a good alternative treatment method in CTS patients with RA.
    Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 07/2007; 137(23-24):347-52. · 1.82 Impact Factor
  • O. Armagan, A. Ekim, C. Oner
    European journal of pain (London, England) 01/2006; 10. · 3.37 Impact Factor
  • A. Ekim, O. Armagan, C. Oner
    European journal of pain (London, England) 01/2006; 10. · 3.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: To investigate the efficacy of low level laser therapy (LLLT) in fibromyalgia patients. Materials and Methods: Thirty-four fibromyalgia patients were randomly assigned to LLLT (n = 16) and placebo laser groups (n = 16). Outcome measures included number of tender points (NTP), Fibromyalgia Impact Questionnaire (FIQ), morning stiffness, global improvement as reported on a verbal scale (VSGI), and total myalgia score. Clinical evaluations were performed before, immediately after, and six months after the treatment. Results: In the LLLT group, significant improvement was observed in clinical parameters at the end of the treatment (p < 0.01). On the other hand, significant improvements were observed only in the number of tender points and morning stiffness in the placebo group (p < 0.05). In comparing the groups, significant improvements were detected in scores of FIQ, VSGI, and total myalgia in the active laser group (p < 0.05). The clinical evaluations performed after six months demonstrated improvements in the clinical parameters only in the LLLT group (p < 0.05). When the groups were compared with each other, significant improvements were found in the LLLT group (p < 0.05). Conclusion: Our results suggest that LLLT has both short-and long-term effectiveness in the treatment of fibromyalgia.
    Journal of Back and Musculoskeletal Rehabilitation 01/2006; 19:135-140. · 0.61 Impact Factor
  • A. Ekim, O. Armagan, C. Oner
    European journal of pain (London, England) 01/2006; 10. · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids. Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months. All patients received calcium supplementation 1,000 mg and vitamin D 400 IU daily. Bone mineral density (BMD) of the lumbar spine, femoral neck, and trochanter was measured annually using dual-energy X-ray absorptiometry. Bone metabolism measurements included urinary deoxypyridinoline (DPD), serum bone alkaline phosphatase (BAP), and serum osteocalcin (OC). Over 2 years, the lumbar spine (4.34%, P < 0.001), femoral neck (2.52%, P < 0.05), and trochanteric (1.29%, P < 0.05) BMD in the alendronate group increased significantly. The sCT treatment increased lumbar spine BMD (1.75%, P < 0.05), whereas a significant bone loss occurred at the femoral neck at month 24 (-3.76%, P < 0.01). A nonsignificant decrease in the trochanteric region was observed in the sCT group (-0.81%). The difference between the groups with respect to the femoral neck and trochanteric BMD was statistically significant ( P < 0.001 and P < 0.05, respectively). The decreases in urinary DPD (-21.87%, P < 0.001), serum BAP (-10.60%, P < 0.01), and OC (-19.59%, P < 0.05) values were statistically significant in the alendronate group, whereas nonsignificant decreases were observed in the sCT group (-5.77%, -1.96%, and -4.31%, respectively). A significant difference was found in the DPD and BAP levels between the two treatment groups in favor of the alendronate group at all time points ( P = 0.001 and P < 0.05, respectively). The results of this study demonstrated that alendronate treatment produced significantly greater increases in the femoral neck BMD and greater decreases in bone turnover than intranasal sCT in RA patients receiving low dose glucocorticoids.
    Rheumatology International 12/2005; 26(1):21-9. · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies revealed trisomy 7 as a chromosomal abnormality in non-neoplastic disorders such as rheumatoid arthritis (RA). In the present study, we investigated the presence of trisomy 7 in the synovial fluid cells of patients with RA using fluorescence in situ hybridisation (FISH) analysis. Synovial fluid from 15 patients with RA was collected from knee joints. The control group consisted of seven patients with traumatic synovial effusion in their knee joints. The arthrocenteses were performed under aseptic conditions. Dual-colour FISH analysis was performed using chromosome-7-specific LSI D7S522 (7q31) and chromosome-5-specific LSI EGR1 (5q31)/D5S721 (5p15.2) probes on the slides prepared from synovial fluid of RA patients and controls. The slides of our cases were analysed using two different DNA probes. When the slides hybridised with chromosome-5-specific probes were analysed, no trisomic or monosomic cells were revealed in both patients and controls. However, in eight of 15 patients, trisomy 7 occurred in variable percentages of cells (23% to 48%) of synovial fluid. No monosomic 7 cells were detected in these specimens. All control cases were disomic for chromosome 7. The results of the present investigation suggest that trisomy 7 may play a role in the pathogenesis of synovial hyperproliferation in RA.
    Rheumatology International 11/2005; 25(8):571-5. · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to perform serological testing to screen for celiac disease (CD) among premenopausal women with idiopathic osteoporosis and to investigate the bone turnover in patients who are seropositive for CD. We studied 89 premenopausal women with idiopathic osteoporosis. The serological screening protocol was based on a two-level evaluation. The first level consisted of determining serum level of IgA antigliadin antibodies (AGA). Subjects who were negative for IgA AGA were classified as not having CD, while samples testing positive for IgA AGA underwent a second level of the screening process. For the second level of screening, the serum IgA endomysial antibody (EMA) test was performed. Bone metabolism was evaluated by serum calcium (Ca), phosphorus, alkaline phosphatase, parathyroid hormone (PTH), 25 (OH) vitamin D, osteocalcin (OC), urinary deoxypyridinoline (dPD), and 24-h urinary calcium levels. Of the 89 patients evaluated, 17 were found to have positive IgA AGA tests (19%) and 9 were found to be positive for EMA (10.11%). EMA-positive patients showed lower values of serum Ca (p<0.05) and 25 (OH) vitamin D (p<0.01) and significantly higher values of PTH (p<0.01) compared with the EMA-negative patients. The level of urinary dPD was found to be significantly higher in EMA-positive patients (p<0.05). The results of this study suggest that all patients with idiopathic osteoporosis should be screened for CD by measurement of EMA. Additionally, we believe that serological screening for CD and detection of such patients will allow determination of the most convenient treatment strategies for osteoporosis.
    Clinical Rheumatology 07/2005; 24(3):239-43. · 2.04 Impact Factor
  • Rheumatology International 08/2004; 24(4):252-3. · 2.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the analgesic efficacy of low power laser therapy in patients with knee osteoarthritis (OA). The study design was randomised, placebo-controlled and single blinded. Sixty patients with knee OA according to the American College of Rheumatology criteria were included and randomly assigned to three treatment groups: active laser with dosage of 3 J/per painful point, active laser with a dosage of 1.5/J per painful point and placebo laser treatment groups. A Gal-Al-As diode laser device was used as a source of low power laser with a power output of 50 mW and a wavelength of 830 nm. The patients were treated 5 times weekly with 10 treatments in all. The clinical assessments included Western Ontario and McMaster Universities osteoarthritis index (WOMAC) pain, stiffness and physical function subscales. In addition, the intensity of pain at rest and on activation was evaluated on a visual analogue scale. Compared to baseline, at week 3 and at month 6, no significant improvement was observed within the groups. Similarly, no significant differences were found among the treatment groups at any time. With the chosen laser type and dose regimen the results that we obtained in this study, suggest that low-level laser therapy has no effect on pain in patients with knee OA.
    Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 06/2004; 134(17-18):254-8. · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy of electromyographic (EMG) biofeedback treatment in the functional recovery of the hemiplegic hand. A total of 27 patients were randomly assigned to EMG biofeedback or placebo EMG biofeedback groups. Both treatments were applied five times a week for a period of 20 days. In addition, the patients in both groups received an exercise program according to the Brunnstrom's neurophysiologic approach. Goniometric measurements for wrist extension, scale for judging the performance of drinking from a glass, Brunnstrom's stages of recovery for hand, and surface EMG potentials were used for the clinical assessments. All patients were assessed before treatment and after 20 treatment sessions. The results showed that there were statistically significant improvements in all variables in both groups, but the improvements in active range of motion and surface EMG potentials were significantly greater in the EMG biofeedback group at the end of the treatment. Our study demonstrates the potential benefits of EMG biofeedback in conjunction with neurophysiologic rehabilitation technique to maximize the hand function in hemiplegic patients.
    American Journal of Physical Medicine & Rehabilitation 12/2003; 82(11):856-61. · 1.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The intent of this study was to assess the effect of low-dose methotrexate treatment on bone mineral density (BMD) in patients with early rheumatoid arthritis (RA). Forty-six premenopausal women with early RA not previously treated with disease-modifying antirheumatic drugs or corticosteroid were randomized to 7.5 mg/week of methotrexate or 2 g/day of sulphasalazine for 18 months. Bone mineral density of the lumbar spine, femoral neck, and trochanter was measured using dual-energy X-ray absorptiometry (DEXA). Biochemical studies included serum calcium, phosphorus, total alkaline phosphatase, beta-2 microglobulin, parathyroid hormone and 25-hydroxyvitamin D(3) concentrations, spot urinary calcium, and 24-h urinary calcium excretion. Disease activity was assessed by modified disease activity score (DAS 28), and functional impairment was estimated by the Health Assessment Questionnaire. No significant difference in BMD of the lumbar spine, femur neck, or trochanter was observed at 18 months in either group. There was also no significant change in the biochemical parameters of both groups. Our findings suggest that low-dose methotrexate has no negative effect on BMD in premenopausal RA patients.
    Rheumatology International 10/2003; 23(5):231-5. · 2.21 Impact Factor